For EGFR PET tracers without treatment analogue, e.g., 18F-MPG, 11C-PD153035 and 18F-IRS, studies have shown that tumor tracer uptake could be quantified and that this was predictive for the presence of an EGFR mutation and for TKI therapy response (45–47). Here, EGFR is linked to neoplasm.